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The relevance of mitochondrial phosphate carrier (PiC),
encoded by SLC25A3, in bioenergetics is well accepted. How-
ever, little is known about the mechanisms mediating the cellu-
lar impairments induced by pathological SLC25A3 variants. To
this end, we investigated the pathogenicity of a novel compound
heterozygous mutation in SLC25A3. First, each variant was
modeled in yeast, revealing that substituting GSSAS for QIP
within the fifth matrix loop is incompatible with survival on
non-fermentable substrate, whereas the L200W variant is func-
tionally neutral. Next, using skin fibroblasts from an individual
expressing these variants andHeLa cells with varying degrees of
PiC depletion, PiC loss of 60% was still compatible with
uncompromised maximal oxidative phosphorylation (oxphos),
whereas lowermaximal oxphos was evident at85% PiC deple-
tion. Furthermore, intact mutant fibroblasts displayed sup-
pressed mitochondrial bioenergetics consistent with a lower
substrate availability rather than phosphate limitation. Thiswas
accompanied by slowed proliferation in glucose-replete
medium; however, proliferation ceased when only mitochon-
drial substrate was provided. Both mutant fibroblasts and
HeLa cells with 60% PiC loss showed a less interconnected
mitochondrial network and a mitochondrial fusion defect
that is not explained by altered abundance of OPA1 or
MFN1/2 or relative amount of different OPA1 forms. Alto-
gether these results indicate that PiC depletion may need to
be profound (>85%) to substantially affect maximal oxphos
and that pathogenesis associated with PiC depletion or loss of
function may be independent of phosphate limitation when
ATP requirements are not high.
The mitochondrial phosphate carrier (PiC),4 encoded by the
nuclear gene SLC25A3, catalyzes the transport of inorganic
phosphate (Pi) into the mitochondrial matrix (for a review, see
Ref. 1); transport is electroneutral and either in symport with
H or in exchange for OH. PiC is a typical member of the
family of mitochondrial inner membrane carriers with six
transmembrane segments, 3-fold symmetry, and N and C ter-
mini projecting into the intermembrane space (2). SLC25A3
has alternatively spliced forms of exon 3 (referred to as exon 3A
and 3B) giving rise to PiC-A and PiC-B isoforms. PiC-B is
expressed ubiquitously, whereas PiC-A is confined to cardiac
and skeletal muscle (3, 4). PiC-A has a 3-fold higher transport
affinity for Pi, whereas PiC-B has a 3-fold highermaximal trans-
port rate (5). Turnover rate has been estimated at 50,000/s at
25 °C, which is high among carriers (6).
The transport characteristics of PiC favor it as the most
important, or only, means of supplying Pi for oxidative phos-
phorylation (oxphos) as well as for other Pi-dependent pro-
cesses within thematrix such as Ca2 buffering. The functional
importance of the PiC was first demonstrated in yeast (Saccha-
romyces cerevisiae) that exhibited delayed growth or failed to
grow on non-fermentable substrate when deleted forMIR1, the
yeast homologue of PiC (7). That the yeast MIR1mutant fails
to thrive specifically when grown on mitochondrial substrates
supports the relevance ofMIR1 for oxphos.
Fundamental aspects of Pi transport into mammalian mito-
chondria and its role in oxphos have been known for decades.
However, only very recently has the role of PiC in oxphos and
other aspects of mitochondrial function such as in control of
the permeability transition pore been directly tested in mam-
mals. This was achieved using mouse models of conditional
heart-specific PiC depletion (8, 9) and depletion of PiC in HeLa
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cells (10) and through the discovery of pathologic variants in
the human gene (11–13). These variants are both in exon 3A,
specifically c.158–9A3G and c.215G3A, which each cause a
frameshift and absence of protein. Functional analyses in skel-
etal muscle biopsy from homozygous individuals revealed
greatly suppressed pyruvate and succinate oxidation rates
despite elevated rates of maximal electron transport chain
activity (11). Phenotypically, the individuals harboring these
exon 3A mutations displayed muscle-related abnormalities
soon after birth, namely elevated blood lactate, hypertrophic
cardiomyopathy, and skeletal muscle hypotonia.
The first variants in SLC25A3 that potentially impact both
PiC-A and PiC-B were recently described by one of us in a case
report (13). An infant was diagnosed prenatally with cardiac
hypertrophy, subsequently required a heart transplant, and is
stable. There was no evidence of lactic acidosis or of skeletal
muscle dysfunction. Whole-exome sequencing revealed a
compound heterozygous mutation in SLC25A3: c.599T3G
(p.L200W) and 22c.886_898delGGTAGCAGTGCTTins-
CAGATAC23 (p.Gly296_Ser300delinsGlnIlePro). These rep-
resent two novel variants in SLC25A3 and impact both PiC
isoforms. Protein modeling predicted both variants to be path-
ogenic (13).
Although the relevance of PiC in bioenergetics and in human
health is now understood, little is known about its role at the
cellular level and the specific mechanisms mediating the cellu-
lar impairments induced by pathological PiC variants (11, 12).
For example, PiC depletion likely affects mitochondrial ATP
production that is central to mitochondrial fusion and mito-
chondrial quality control. In the current report, we use yeast
andmammalian cell models, including primary fibroblasts har-
boring the compound heterozygous mutation, to elucidate the
pathogenicity of the novel variants, both individually and when
co-expressed as heterozygous variants. In addition, we study
the impact of PiC depletion on energy metabolism and mito-
chondrial dynamics.
Results
The PICQIP Mutant, but Not PICL200W, Is Non-functional—
The identified human PiC mutations were each transformed
into themir1 yeast strain (Fig. 1A). Additionally, a humanized
version of yeast Pic1p (PICHum) was included to delineate con-
sequences of themutation from that of the inherent differences
between human and yeast proteins. The PICL200W missense
variant, which models the point mutation, was similar to wild-
type (WT) human PiC in terms of protein amount and func-
tional growth (Fig. 1, A and B). Furthermore, there was no
expression or growth defect observed for PICL200W even at ele-
vated temperature (37 °C) (Fig. 1, C and D). In contrast, the
PICQIP variant, which models the GSSAS 3 QIP mutation,
resulted in a slightly decreased protein level (see Fig. 1A, com-
pare QIP with Hum) and the inability to survive in respiratory
medium (Fig. 1B), consistent with a defect in oxphos. These
effects cannot be attributable to the humanized construct
because reconstitution with PICHum, which expresses the wild-
type GSSAS sequence, showed comparable expression and
functionality toWT yeast at both optimal and higher tempera-
tures (Fig. 1, A–E).
Because these novel PiC mutations were identified in a com-
pound heterozygote, we used the yeast model to ask whether
PICQIP could act in a dominant negative manner. To this
end, pRS316PICQIP was transformed into mir1(pRS315),
mir1(pRS315PIC1), mir1(pRS315PICL200W), or mir1
(pRS315PICHum) strains. Growth on fermentable substrate was
normal for all strains (Fig. 1D) and was hindered on non-fer-
mentable substrate only when two copies of PICQIP were
expressed. Thus, PICQIP is not sufficient to cause problems in
expression and respiratory growth in yeast when a functional
FIGURE1.Modeling thenovel compoundheterozygousmutation inhumanPiCusingyeast.A, steady-stateprotein expression andgrowthanalyses of PiC
variants and humanized PiC in comparison with WT. Immunoblotting for Pic1p and the loading controls Tom70p and Atp2p was done using yeast whole cell
extracts. B, 1:4 dilutions of the same set of strains were tested for functional growth using the indicatedmedia. Plates were incubated at 30 or 37 °C for 3 days
except for YPEG at 37 °C, whichwas cultured for 10 days. C, steady-state protein expression and growth analyses ofWT PIC, PICL200W variant, and PICHum in the
presence or absence of co-expressed PICQIP as inA.D, 1:4 dilutions of the same set of strainswere tested for functional growth using the indicatedmedia at the
designated temperature. Plates were incubated for 3 days (YPD at 30 °C), 5 days (YPD at 37 °C and YPEG at 30 °C), or 13 days (YPEG at 37 °C). E, quantification
of PIC or PICL200W protein amounts at 37 °C in the presence or absence of PICQIP (n 9). Data are presented as means; error bars represent S.E. n.s., differences
not significant. EV, empty vector; YPD, 1% yeast extract, 2% peptone, 2% dextrose; YPEG, 1% yeast extract, 2% peptone, 1% ethanol, 3% glycerol.
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copy of PIC (WT, L200W, or humanized) is present (Fig. 1, C
and D).
Delayed Proliferation and a Lower Functional Respiratory
Capacity in PiC Compound Mutant Fibroblasts—We obtained
primary skin fibroblasts from the individual expressing the
compound heterozygous PiC mutation (PiC mutant) (13) as
well as from four control (Ctrl) individuals. The tendency for a
lower expression of PiC protein in the yeast cells transformed
with theQIPmutation prompted us to evaluate PiCmRNA and
protein expression in the fibroblasts. For quantitative PCR,
primers recognizing mRNA for the PiC-A and PiC-B isoforms
were validated using human skeletal myoblasts, which are
known to predominantly express PiC-B and then to up-regulate
PiC-A upon differentiation into myotubes (Fig. 2A). Quantita-
tive PCR analysis using these validated primers revealed
unchangedmRNA levels for both isoforms in PiCmutant fibro-
blasts (Fig. 2A; note that PiC-B is the predominant isoform in
fibroblasts). Differently, immunoblot analysis using an anti-
body raised against the full-length PiC protein showed that PiC
expression was 40% of the level in Ctrl fibroblasts as deter-
mined using fibroblasts from four healthy individuals (Fig. 2B;
the representative blot shows two of the control fibroblast
lines); the antibody typically revealed two bands, and only the
upper bandwas quantified. Lowermolecular weight fragments,
which would indicate cleavage products, were not detected. In
contrast to this lower PiC protein abundance, the protein
expression level ofmany othermitochondrial proteinswas sim-
ilar between PiC mutant and Ctrl cells (Fig. 2B), pointing to a
selective decrease in PiC protein in PiC mutant cells.
To investigate the effect of the PiC compound heterozygous
mutation on proliferative capacity in a mammalian system, the
primary skin fibroblasts were grown in parallel with Ctrl skin
fibroblasts in different media. PiC mutant cells grown in glu-
cose-rich medium appeared healthy but divided more slowly
with a doubling time that was approximately twice the Ctrl rate
(Fig. 3, upper andmiddle panels) whether cells were grown in 5
mM glucose or in 25 mM glucose. When cells were challenged
with medium free of glucose and containing only mitochon-
drial substrates (-hydroxybutyrate and glutamine), Ctrl fibro-
blasts continued to proliferate although at a much slower rate.
In contrast, PiC mutant fibroblasts could not maintain prolif-
eration when glucose was unavailable (Fig. 3, lower panel).
Although the yeast models indicated the lack of a dominant
negative effect of the GSSAS 3 QIP mutation, the patient-
derived fibroblasts suggested that the presence of the mutation
rendered the PiC protein unstable, leading to substantially
lower levels of PiC protein, which could suppress oxphos. To
determine whether this occurred, O2 consumption (JO2) was
measured. Intact PiC mutant fibroblasts grown and studied in
low or high glucose (plus 4 mM glutamine) had 50% of the
basal mitochondrial JO2 (i.e. minus the rate measured after
addition of antimycin to inhibit complex III of the electron
transport chain) of the Ctrl cells (Fig. 4A shows raw O2 traces
from an experiment, and Fig. 4B shows group averages). To
indirectly determine whether a Pi limitation on oxphos could
account for the lower basal JO2, we evaluated the leak-depen-
dent mitochondrial JO2 (i.e. after addition of oligomycin to
inhibit the ATP synthase) and the uncoupler-driven JO2 (using
FCCP to evaluate electron transport chain capacity under the
prevailing substrate conditions); if a Pi limitation onoxphoswas
the sole driver of the lower basal JO2 in PiC mutant cells, then
leak-dependent and uncoupled JO2 should remain similar to
that in Ctrl cells. Differently, both of these were lower in PiC
mutant cells, pointing to a broader defect that results in not
only lower basal JO2 but also decreased functional capacity of
the electron transport chain.
FIGURE 2. Lower PiC protein expression in primary fibroblasts harboring the compound heterozygous PiC mutation. A, mRNA, as assessed by quanti-
tative PCR analysis, of isoforms A and Bwas unchanged by the PiCmutant. Ctrl data were obtained from fibroblasts from three normal individuals; PiCmutant
datawere obtained from twodifferent passages of the fibroblasts expressing the compound SLC25A3mutation. As controls for identification of isoformA and
B mRNA, mRNA was isolated from primary human skeletal myoblasts and myotubes (upper panels); myotubes were expected to show up-regulated PiC-A
comparedwithmyoblasts.B, left panels, example of an immunoblot fromPiCmutant fibroblasts andCtrl fibroblasts from twodifferent individuals.Arrow, band
used toquantify PiC abundance.Right panel, quantification fromCtrl fibroblasts from fournormal individuals (each testedat threedifferent passages) and from
five separate passages (less thanpassage 10) of the PiCmutant fibroblasts. For eachgenotype, band intensitywas first normalized to that of-tubulin. Data are
presented asmeans, and error bars represent S.E. except for the skeletalmuscle cells, which are each from a single sample. C-I, C-II, and C-III, complexes I, II, and
III; Cyto-c and cyt c, cytochrome c.
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To further investigate the possibility of a Pi limitation on
oxphos in PiCmutant fibroblasts, JO2wasmeasured in permea-
bilized cells supplied with either pyruvatemalate (Fig. 4B) or
succinate rotenone (not shown) and in the presence of satu-
ratingADP (maximal phosphorylating JO2; state 3), followed by
addition of oligomycin and then of FCCP. There were no dif-
ferences between Ctrl and PiC mutant cells for either of the
substrates or any of the conditions. Notably, state 3 JO2 was not
different, indicating the availability of sufficient Pi to drivemax-
imal oxidative phosphorylation in PiC mutant cells.
HeLa Cells with Substantial PiC Depletion Can Sustain Oxi-
dative Phosphorylation—The continued presence in PiC
mutant fibroblasts of oxphos, despite the60% lower PiC pro-
tein abundance, suggested either that the capacity of PiC is far
in excess of its requirement for oxphos in these cells or that
alternative sources of Pi are available to the matrix. To further
test whether lower PiC can be compatible with substantial
oxphos, PiC was acutely depleted in HeLa cells using siRNA;
two different siRNA duplexes were investigated (kd1 and kd2;
Fig. 5). By 72 h post-siRNA introduction, PiCproteinwas15%
of control levels (Fig. 5A). In contrast, the protein expression
FIGURE 3. Slower proliferation rate in primary skin fibroblasts harboring
the compound heterozygous PiC mutation. Cells tested in glucose plus
glutamine had been growing in that substrate condition for two to three
passages. Cells tested in -hydroxybutyrate (BHB) plus glutamine (no glu-
cose) were switched to that condition the day before cell counting was
started.DMEM10%FBSwasusedas thebasemediumthroughout.n3–6
growth curves/genotype derived from cells at different passages (less than
passage 10). In the 25 mM glucose and no glucose conditions, Ctrl cells were
from two different subjects (n  3/subject). In the 5 mM glucose condition,
Ctrl cells were from one subject. Data are presented as means; error bars rep-
resent S.E. Doubling timewas significantly longer in PiCmutant cells; p values
were calculated using an unpaired t test. fibro, fibroblasts.
FIGURE 4. Suppressed bioenergetics in intact but not permeabilized PiC
mutant skin fibroblasts. A, raw O2 traces from a single experiment where a
Ctrl line and the PiC mutant cells were studied in parallel. Cells were grown
and the experiment was performed in 5 mM glucose  4 mM glutamine as
substrates. Values are means S.D. with six technical replicates each. Oligo-
mycin (Oligo) was injected to inhibit ATP synthase to measure leak-depen-
dent respiration. Capacityof theelectron transport chainunder theprevailing
substrate condition was determined using the chemical uncoupler FCCP.
Finally, antimycin was injected to inhibit the electron transport chain to
reveal non-mitochondrialO2 consumption.Note that protein abundancewas
similar for Ctrl andPiCmutant cells (10%higher formutant cells).B andC, all
values aremitochondrial O2 consumption rates calculated by subtracting the
O2 consumption rate measured after antimycin. The basal rate is the rate
measured in the absence of inhibitors or uncoupler. Cells were grown in the
indicated substrate conditions for two to three passages before testing in
those conditions. p values are as follows: ***, p  0.01 from Tukey post
hoc test after two-wayANOVA (p 0.011 for genotype	 JO2 condition inter-
action); **, p 0.03 from two-way ANOVA (genotype	 JO2 condition inter-
action not significant; p  0.03 for genotype main effect; p  0.001 for JO2
conditionmain effect). C, cells were cultured in the indicatedmedia and then
preincubated in those media for 45 min in 0 CO2 before being switched to
intracellular medium containing 10 mM pyruvate, 2.5 mM malate, saturating
ADP, andapermeabilizing reagent (see “Experimental Procedures” for further
details). Permeabilizationwas confirmedby showing robust succinate-driven
O2 consumption; succinate does not cross the plasma membrane (not
shown). Data were normalized to total cellular protein from parallel plates of
intact cells.n3/genotype fromcells at differentpassages (less thanpassage
10). In B and C, data are presented as means, and error bars represent S.E. For
the 5 mM glucose condition, n 4/genotype from cells at different passages
(less than passage 10). For the 25 mM glucose condition, four separate Ctrl
fibroblast lines were tested, each in triplicate (three different passages); trip-
licates were averaged. Data from PiC mutant cells were split into parallel cul-
tures for the different controls and then tested at three different passages
each. Thus, n 4/genotype for 25 mM glucose.
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level of other mitochondrial proteins was unchanged 72 h
post-siRNA treatment (Fig. 5A). Cell proliferation, measured
using cells seeded at 48 h post-siRNA addition, was delayed by
PiC depletion (Fig. 5B). Measurements of JO2 in permeabilized
cells revealed a 30–40% suppression of state 3 JO2 with either
pyruvate  malate (Fig. 5C) or succinate (rotenone; not
shown), whereas leak-dependent JO2 and uncoupled JO2 were
unchanged by PiC knockdown (Fig. 5C); these results are con-
sistent with a Pi limitation on oxphos as the cause of the lower
state 3 JO2. In intact cells, substantial PiC depletion had no
effect on basal, leak-dependent, or uncoupler-driven JO2. We
further investigated oxphos inHeLa cells that had a lesser acute
depletion of PiC; cells were depleted by 60–65% (Fig. 5D),
which is similar to the extent of the PiC decrease in PiCmutant
fibroblasts (Fig. 2B). In contrast to permeabilized HeLa cells
with85% decrease in PiC, permeabilized HeLa cells express-
ing slightly more PiC had the same maximal phosphorylating
JO2 as Ctrl HeLa cells. Altogether, the data from intact and
permeabilized HeLa cells with different levels of PiC deletion
further support that at least some oxphos can be maintained
despite substantial PiC depletion.
Altered Mitochondrial Morphology in PiC Compound
Mutant Fibroblasts and in HeLa Cells with Acute PiC
Depletion—Emerging literature supports a mutual relationship
between mitochondrial function and form (15). Indeed, visual-
ization of mitochondrial morphology in fibroblasts expressing
mitochondrial matrix-targeted DsRed1 (mtDsRed) revealed
fewer elongatedmitochondria in PiCmutant than in Ctrl fibro-
blasts (Fig. 6, A and B). Furthermore, in HeLa cells with60%
decrease in PiC a similar change in themitochondrial formwas
obtained (Fig. 6C). A decrease in the fraction of elongated
organelles can result from decreased mitochondrial fusion or
increased mitochondrial fission.
Less Fusion Activity in PiC Compound Mutant Fibroblasts
and in HeLa Cells with Acute PiC Depletion—To evaluate
directly whether the distinct mitochondrial morphology in PiC
patient and control fibroblasts can result fromdifferent levels of
interorganellar continuity and fusion events, the cells were co-
FIGURE 5. Acute PiC depletion in HeLa cells is still associated with substantial phosphorylating O2 consumption. A, immunoblots from HeLa cells
exposed for 72 h to one of two different siRNA duplexes targeting PiC or scrambled controls. For each genotype, bands were normalized to either succinate
dehydrogenase subunit A (SDHA) or -tubulin. n 3/genotype. B, growth curves in HeLa cells exposed to siRNA for 72 h and grown in DMEM 25mM glucose
4mMglutamine.p values (doubling times) are fromanunpaired t test.n3/genotype.C,mitochondrial bioenergeticsmeasured in cells exposed tooneof two
different siRNA duplexes for 72 h, grown and tested in either DMEM 25mMglucose 4mMglutamine (Intact), or permeabilized and suppliedwith pyruvate
andmalate (Permeabilized). See “Experimental Procedures” and Fig. 4 for further details. n 3–5/genotype.D, immunoblots showing lesser depletion of PiC in
HeLa cells exposed to siRNA for 48 h. Cells were grown in DMEM 25mMglucose 4mMglutamine, andmitochondrial bioenergetics weremeasured in that
medium (Intact) or subsequently permeabilized and supplied with pyruvate andmalate (Permeabilized). See Fig. 4 for further details. n 3–5/genotype. In all
panels, data are presented asmeans, and error bars represent S.E. For the immunoblots, p values are as follows: ***, p 0.01; **, p 0.02; *, p 0.046 (unpaired
t test). For the JO2 measurements, p values are as follows: ***, p  0.001; *, p  0.035 (Tukey post hoc tests following two-way ANOVA with significant
genotype 	 JO2 condition interaction). Two different siRNA duplexes were used (kd1 and kd2), and controls were run with each (Ctrl 1 and Ctrl 2). Oligo,
oligomycin; C-I, C-II, and C-III, complexes I, II, and III; cyto-c, cytochrome c.
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transfected with cDNA encoding mtDsRed and mitochondrial
matrix-targeted photoactivatable GFP (mtPA-GFP). Using
confocal microscopy, a time series of fluorescence images was
recorded, and 25-m2 square-shaped areaswere illuminated by
a pulsed laser to photoactivate mtPA-GFP (16, 17). Mitochon-
drial matrix continuity and connectivity are unveiled by the
diffusion of the photoactivated PA-GFP to the regions outside
the 2 photon illuminated area. Image time series indicated less
mtPA-GFP diffusion in PiCmutant than inCtrl fibroblasts (Fig.
7A). To quantify connectivity, the time course of the ratio of
FmtPA-GFP and FmtDsRed was calculated for the region of photo-
activation (RPA) (Fig. 7A). The slower decay of the fluorescence
ratio in the RPA indicates a decrease in the combined activity of
mitochondrial network formation (40 s) and mitochondrial
fusion andmitochondrial movements (500 s) in the PiCmutant
fibroblasts (Fig. 7B). To validate fusion events, reciprocal
spreading of mtPA-GFP and mtDsRed among mitochondria
that were not continuous at the time of mtPA-GFP photoacti-
vation was sought. The fusion events were quantitatively ana-
lyzed by the progression of the distribution of mtPA-GFP fluo-
rescence between the images collected within the first 24 s and
8 min after photoactivation. The result of manual counting
indicates less mitochondrial fusion activity in the PiC mutant
fibroblasts. The total fusion numbers were decreased signifi-
cantly in the mutant fibroblasts (Fig. 7C). Although Fig. 7C
shows fusion event number for only one control fibroblast line
that was studied side by side with the PiC mutant, the fusion
event numbers were very similar in other control fibroblast
lines (7.3  0.3 versus 6.5  0.1, 7.5  0.1, and 6.4  0.3; n 
3–7). Conversely, the average duration of individual fusion
events was similar in both PiCmutant fibroblasts and Ctrl (Fig.
7D). Furthermore, the distribution of different fusion types in
terms of rapid reversal and orientations (Fig. 7E) did not show
any alterations in PiC mutant fibroblasts as compared with the
Ctrl. In HeLa cells with60% decrease in PiC (attained by two
different siRNA duplexes, kd1 and kd2), the mitochondrial
connectivity and fusion activity were similarly decreased as in
the mutant fibroblasts (Fig. 7, F–I).
ATP produced by oxphos is required to maintain the fusion
promoting activity of OPA1, the inner mitochondrial mem-
brane fusion protein (18, 19). To test whether the decreased
mitochondrial fusion activity can be attributed to a change in
OPA1 or another mitochondrial fusion protein, immunoblot-
tingwas performed inwhole cell lysates. The total abundance of
OPA1was unaltered in PiCmutant fibroblasts (Fig. 8A). A shift
in OPA1 immunoreactivity from the high to the lower molec-
ular weight bands indicates a decrease in the fusion-competent
forms (as induced by FCCP; Fig. 8B). However, no change in the
relative abundance of the high and lowmolecular weight bands
appeared in the PiC mutant fibroblasts (Fig. 8B). Among the
main outer membrane fusion proteins, mitofusin 1 (MFN1)
was slightly but significantly decreased, whereas mitofusin 2
(MFN2) and the main fission protein DRP1 were unchanged
(Fig. 8A). In HeLa cells with 60% PiC depletion, the abundance
of none of these fusion and fission proteins was altered (Fig.
8C). Collectively, the results in two different paradigms of PiC
depletion show suppressedmitochondrial fusion activity.How-
ever, the decreased fusion activity cannot be attributed to pro-
cessing of OPA1 to fusion-incompetent forms or to substantial
loss of another fusion protein.
Discussion
The novel compound heterozygous mutations in SLC25A3
described here and previously (13) were associated in vivowith
respiratory distress and hypertrophic cardiomyopathy but with
unremarkable function of other organs, including skeletal mus-
cle (13). The pathological potential of the novel SLC25A3muta-
tions was not tested directly and was our aim. Here we report
that the point mutation is likely to be functionally neutral,
whereas the GSSAS 3 QIP variant has relevance compatible
with a loss of function. Furthermore, the GSSAS3QIP variant
does not obligatorily act as a dominant negative. However, in
primary fibroblasts harboring the compound heterozygous PiC
mutation and thus one potentially functional allele, PiC protein
abundance was substantially lower, and the cells were not phe-
notypically normal; the most dramatic phenotype was a prolif-
eration time thatwas approximately half the control rate and an
inability to divide when supplied with only mitochondrial sub-
strates. PiC mRNA was unaffected by the mutations. Thus the
compound heterozygous PiCmutation has a functional impact
inmammalian cells with instability of the PiC protein as a likely
initiating factor. We also found in patient fibroblasts, as well as
HeLa cells with different levels of acute PiC loss, that PiC protein
could be substantially depleted before oxidative phosphorylation
was suppressed. This suggests that the PiC can be expressed in
excess of oxphos needs or that other PiC transport mechanisms
can compensate. However, PiCmutant fibroblasts could not pro-
liferate inmitochondrial substrate, suggesting that a partial deple-
FIGURE 6.Mitochondrial morphology in primary PiCmutant fibroblasts and PiC-deficient HeLa cells.Mitochondrial morphology was scored as follows:
fragmented, mainly small and round; partly fragmented, intermediate, mixture of round and shorter tubulated; normal, tubulated, long and higher intercon-
nectivity; elongated, very long, tubulated. The percentage of cellswith the indicatedmitochondrialmorphologieswas determined as a percentage of the total
number of DsRed-transfected cells counted (18 cells per experiment; n 4 independent experiments). A, representative figures of the different mitochon-
drial forms in Ctrl and PiCmutant fibroblasts. B, distribution of the different type ofmitochondria in primary fibroblasts. C, distribution of the different types of
mitochondria after PiC silencing in HeLa cells. Scr., scrambled siRNA; PiC kd1 and kd2, two different PiC-specific duplexes.
PiC inMitochondrial Metabolism, Dynamics, and Cell Survival
DECEMBER 9, 2016•VOLUME 291•NUMBER 50 JOURNAL OF BIOLOGICAL CHEMISTRY 26131
 at SEM
M
ELW
EIS U
N
IV
 O
F M
ED
ICIN
E on February 16, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
tion of PiC can become pathogenic when demand for mitochon-
drial ATP is high. Finally, PiC mutant fibroblasts, as well as HeLa
cells with acute PiC loss, had a more fragmented mitochondrial
networkandslower rateof innermitochondrialmembrane fusion,
raising the possibility that organ pathology might be contributed
by dysfunctional mitochondrial processes other than, or in addi-
tion to, suppressed oxphos.
The mir1 yeast strain transformed with one or both of the
newly identified human PiC variants was used to evaluate the
functional relevance of these variants. Leu-200 is conserved
among mammalian species and in yeast and is located within a
region that is fully to strongly conserved between human and
yeast. Based on themodel of PiC determined by Bhoj et al. (13),
Leu-200 resides in a small matrix helix that connects trans-
FIGURE 7. Mitochondrial continuity and fusion activity in primary fibroblasts. A, image time series showing a representative fibroblast before and after 2P
photoactivationofmtPA-GFP (white squares) at 0 s (first stepof the imaging), 24 s (first stepdirectly afterphotoactivation), 40 s (themtPA-GFPdiffusionwithin the first
16 s of photoactivation), and 500 s (further spreading after 8min). A region of interest for each condition (dashedwhite line) is magnified and shown as PA-GFP only
(green) images for each timepoint.B, the time course of the ratio of FmtPA-GFP and FmtDsRed for the RPA (above) and thedecayof the fluorescence ratio in theRPAat 40
and500s(below).Asterisks indicatesignificantdifferences (p0.05).C, fusioneventrate inprimaryfibroblasts.D, averagefusiontimes.E,distributionofdifferent fusion
types (left) andorientation (right). F–I, HeLa cells treatedwith scrambled siRNAor kd1or kd2duplexes targetingPiC. F, the time course of thenormalized FmtPA-GFP for
the region of photoactivation (RPA) (left) and the decay of the fluorescence ratio in the RPA at 500 s (right). Asterisks indicate significant differences (p 0.05). Scr.,
scrambled siRNA-silenced cells; PiC kd1 and kd2, PiC siRNA-treated cells. G, fusion event rate in silenced HeLa cells. H, average fusion times in silenced HeLa cells. I,
distribution of different fusion types (left) and orientation (right) in silencedHeLa cells. In B, C,D, F,G, andH, error bars represent S.E.
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membrane helices 3 and 4 and interacts with adjacent hy-
drophobic residues near PX(D/E)XX(K/R), the consensus
sequence of all inner mitochondrial membrane carrier pro-
teins. It was predicted that substitution of leucine for trypto-
phan would not be well tolerated due to tryptophan’s large
hydrophobic side chain, which would be exposed to the solvent
and could introduce steric clashes (13). However, the L200W
substitution did not prevent growth onmitochondrial substrate
even at elevated temperature, suggesting that this variant is
neutral. In contrast, the GSSAS 3 QIP variant prevented
growth only on mitochondrial substrate even in unchallenged
yeast and despite only slightly decreased PiC protein abun-
dance. This is in line with a loss-of-function mutation and a
deleterious effect on oxphos. Based on the nomenclature of the
ADP/ATP carrier, GSSAS occurs at matrix loop-connecting
transmembrane helices 5 and 6. The variant replaces very small
(Gly and Ala), flexible (Gly), and polar (Ser) residues for bulky
(Gln), hydrophobic (Ile), and inflexible (Pro) residues. Thus,
GSSAS 3 QIP was predicted to not be well tolerated (13),
which is what we found here. Because previously confirmed
pathological SLC25A3 variants affected only PiC-A (11, 12),
GSSAS3QIP is the first variant that affects both isoforms.
PiCmutant fibroblasts with60% less PiC protein had lower
basal JO2, maximal leak-dependent JO2, and maximal electron
transport chain activity. Changes in bioenergetics caused only
by a Pi limitation on oxphos would be restricted to suppressed
phosphorylating JO2 as we observed in permeabilized HeLa
cells with 
85% PiC loss. In contrast, permeabilized mutant
fibroblasts had similar maximal phosphorylating JO2 as Ctrl
fibroblasts, indicating that Pi did not limit oxphos. Moreover,
lack of a difference in basal or uncoupled JO2 in permeabilized
mutant fibroblasts suggests that the abundance of assembled
respiratory complexes and ATP synthase as well as their ability to
assemble into higher order complexes was unchanged in mutant
fibroblasts. Rather, the decrease in not only basal but also leak-de-
pendent JO2 and maximal electron transport chain activity in
intact mutant fibroblasts is consistent with lower provisioning of
reducing equivalents to the electron transport chain.
The pronounced decrease in JO2 in intact mutant fibroblasts
contrasts with minimal decrease in intact HeLa cells with
greater PiC depletion. This different response to PiC depletion
may arise from long versus short term PiC loss. Another possi-
bility is that mutant PiC protein in fibroblasts induced a stress
response that might not occur in HeLa cells that were depleted
of PiC through suppression of mRNA rather than mutation. In
fact, lower PiC protein was not predicted by either of themuta-
tionswhich are in-frame; indeed,mRNAexpression of bothPiC
isoforms was unaffected. The lower PiC abundance in the
mutation-harboring fibroblasts is also unlikely to reflect natural
variability in translation efficiency or turnover because these
PiC variant cells deviated similarly in their PiC abundance as
compared with fibroblasts from four healthy donors. Rather,
depletion of PiC protein in the mutant fibroblasts may reflect
an inability of PiC to be properly translated or a tendency for
mutant PiC to aggregate, to be misfolded, or to be incorrectly
incorporated into complexes (which likely include dimers as
well as other components such as the adenine nucleotide trans-
locase (20–22)). Such disruptions in PiC protein folding might
induce amild stress response that is partially responsible for the
mitochondrial phenotypes observed in mutant fibroblasts.
The substantial oxphos remaining in permeabilized mutant
fibroblasts and PiC-depleted HeLa cells suggests that the abun-
dance of PiC is in excess of oxphos needs or that alternate Pi
transport pathways compensate for PiC loss. These possibilities
FIGURE 8. Abundance of mitochondrial fusion and fission proteins in PiC-deficient primary fibroblasts and HeLa cells. A, Western blotting of the main
fusion and fission proteins in the Ctrl and PiC-deficient fibroblasts. Left, representative blots; right, normalized protein abundance of the percentage of the
average protein levels of control fibroblast. B, OPA1 isoforms. FCCP (5 M) was used as a positive control to show the mitochondrial uncoupling-induced loss
of the long formofOPA1.C, Western blotting of themain fusion and fission proteins inHeLa cells. Scr., scrambled siRNA-silenced cells; PiC kd, PiC siRNA-treated
cells. Left, representative blots; right, normalized protein abundance of the percentage of the average protein levels of scrambled siRNA-silenced cells. InA and
C, error bars represent S.E.
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are also suggested by observations made in mice with either
60 or 
95% depletion of PiC in the heart (8, 9). Cardiac PiC
depletion of60%was associatedwith verymild cardiac hyper-
trophy and no discernible functional defect (9). Even when PiC
was depleted by 
95%, cardiac function was unaffected for at
least 2weeks, andATP in themitochondrial fractionwas 50%of
normal (8), suggesting compensation at the level of mitochon-
dria or that very little PiC can sustain some level of oxphos.
Using a fresh skeletal muscle biopsy from an individual with a
homozygous c.215G3A mutation affecting only PiC-A, sub-
strate oxidationwas tested using a variety of conditions andwas
clearly suppressed (11). However, the extent of suppression
varied considerably, ranging from as low as 10% of control
(using the lower extent of the control range) to 
30% of con-
trol. Because uncoupler-driven oxidation was within the con-
trol range, the variability in substrate oxidation would not be
due to differences in the capacity to supply reducing equiva-
lents to the electron transport chain or in the capacity of the
electron transport chain itself. Rather, the variability in oxida-
tion reported byMayr et al. (11) could arise fromvariable access
to alternate Pi transport pathways such as the dicarboxylate
transporter, which exchanges succinate or malate for Pi (23).
Generally the PiC has been assumed to be the Pi uptake mech-
anism in mitochondria. Although the present study and those
discussed above cannot distinguish between excess PiC capac-
ity and alternate Pi transport, the observations collectively sug-
gest that this is an important question that needs to be
addressed by future studies.
A shift ofmitochondrialmorphology to a less interconnected
phenotype was present in both PiC mutant fibroblasts and
HeLa cells with quantitatively similar acute PiC depletion. This
shift can result from the observed decrease in mitochondrial
fusion activity. A sensible mechanism to underlie decreased
fusion could be a decrease in fusion-competent OPA1 that is
dependent on oxphos-derived ATP (18, 19). However, neither
total OPA1 nor the relative contribution of the different forms
was altered in mutant fibroblasts or in the PiC-depleted HeLa
cells. A decrease in the amount of the outer membrane fusion
mediator MFN1 or MFN2 could also cause suppression of
mitochondrial fusion (17, 24). Indeed, there was a lower level of
MFN1 in the mutant fibroblasts, but it was unaltered in the
PiC-deficient HeLa cells that displayed a similar mitochondrial
fusion phenotype to the fibroblasts. Furthermore, MFN2 was
unchanged in both PiC-deficient paradigms. Activity of the fusion
proteins can also be affected by posttranslational modifications,
but no specific mechanism appeared likely here and because of
that was not tested. Although the specific molecular mechanism
linking PiC activity to fusion requires further investigation, the
present findings might illuminate a common cause of mitochon-
drial fragmentationobserved in fixed skin fibroblasts derived from
patients with various oxphos impairments with a general trend
that fragmentation increases with severity of the defect (25–28).
Based on the present results, live cell mitochondrial imaging in
single cells might detect even a mild oxphos (or mitochondrial)
defect that remains unnoticeable by JO2 measurements.
The patient harboring the compound heterozygous PiC
mutation had severe hypertrophic cardiomyopathy that
required heart transplantation but did not have skeletal myop-
athy, lactic acidosis, or other obvious organ dysfunction (13). In
contrast, not only hypertrophic cardiomyopathy but also skel-
etal muscle hypotonia and lactic acidosis were symptoms in
individuals with homozygous mutations leading to loss of
PiC-A protein in muscle only (11, 12). PiC-B would still be
expressed; however, there did not appear to be compensation,
and the levels appeared low (12). Parenthetically, it is also not
known to what extent PiC-B can functionally compensate for
PiC-A. The compound heterozygous mutation affects both
PiC-A and PiC-B, and we have shown here that the GSSAS3
QIP variant is deleterious and that the variant(s) can destabilize
PiC protein. However, our data also indicate that some PiC
protein remains. Furthermore, we show that some oxphos
capacity is retained even when PiC protein abundance is quite
low. The latter is also supported bymousemodels of PiC deple-
tion in the heart (8, 9). However, we also show that oxphos
capacity is sensitive to PiC abundance. We propose that these
findings are consistent with confinement of the phenotype of
the compound heterozygous mutation to cardiomyopathy
because of the incessantly high demand for ATP of the heart.
Our study has revealed that PiC depletion is accompanied by
defective cell proliferation and mitochondrial fusion and an
oxphos defect that does not depend on Pi limitation. Thus, the
pathogenesis associated with PiC depletion or loss of function
may, at least in part, reflect these deficiencies. It will also be of
interest to determine whether these deficiencies are a general
feature of pathological PiC variants.
Experimental Procedures
Molecular Biology—YeastMIR1 gene fragment, with 470-bp
5-UTR and 50-bp 3-UTR, was generated by PCR using
GA74-1A genomic DNA as template and cloned into pRS315.
The PIC1mutants, L200W and QIP (replacing amino acid res-
idues 247–258 of yeast Pic1p) as well as a humanized version
(normal human amino acids GSSAS in place of residues 247–
258 of yeast Pic1p) were created by overlap extension (29) and
subcloned into pRS315. For the co-expression studies, PICQIP
was subcloned into pRS316. Construct verification was per-
formed by restriction digest analysis and/or sequencing.
Yeast Strains and Growth Conditions—All yeast strains used
were derived from GA74-1A (MATa, his3–11,15, leu2, ura3,
trp1, ade8 (rho,mit)). The open reading frame ofMIR1 was
replaced with HIS3MX6 by a PCR-based disruption method.
The resulting strain was then transformed with pRS316PIC1
to prevent loss of mtDNA, and the desired strains were gener-
ated by plasmid shuffling. In brief, pRS315, pRS315PIC1,
pRS315PICL200W, pRS315PICQIP, or pRS315PICHumwas trans-
formed into mir1(pRS316PIC1) followed by two selections in
5-fluoroorotic acid to generate clones lacking pRS316PIC1.
Growth studies were performed to evaluate yeast strain func-
tionality. Cultures were inoculated in synthetic complete dex-
trose without leucine (0.17% yeast nitrogen base, 0.5% ammo-
niumsulfate, 0.2% synthetic dropoutmixtureminus leucine, 2%
dextrose), grown overnight at either 30 or 37 °C, spotted in
synthetic completemediumwithout leucine and supplemented
with dextrose or 3% glycerol and 1% ethanol, and incubated at
the indicated temperature and duration.
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To assess whether the PICQIP allele exerts a dominant nega-
tive effect on WT PIC1 or the other PIC alleles, pRS316
or pRS316PICQIP was transformed into mir1(pRS315),
mir1(pRS315PIC1), mir1(pRS315PICL200W), or mir1
(pRS315PICHum). Growth analyses were done as described
above except that synthetic complete dextrose without leucine
and uracil and the same selection medium supplemented with
either dextrose or 3% glycerol and 1% ethanol were utilized for
inoculation and spotting, respectively.
Mammalian Cell Culture—Primary skin fibroblasts were
obtained from the PiC mutant (13) as well as two age-matched
controls and two controls from older individuals, resulting in
fibroblasts from four healthy individuals that were used as con-
trols. Fibroblasts were cultured in DMEM containing 4 mM
glutamine and either 5 mM glucose or 25mM glucose. For some
growth curve experiments, cells were cultured in glucose-free
DMEM containing 4 mM glutamine and supplemented with 5
mM -hydroxybutyrate; this medium forced cells to rely on
mitochondria forATPproduction (30, 31). PiCmutant andCtrl
cells were only used for 10 passages and were always compared
at the same passage number. HeLa cells (ATCC) were cultured
in DMEM containing 25 mM glucose, 4 mM glutamine, and 1
mM pyruvate; HeLa cells were not used beyond passage 14. All
cells were maintained in a 5% CO2, 21% O2 incubator at 37 °C.
Transfections with siRNA and Plasmid DNA—Before silenc-
ing, HeLa cells were plated in antibiotic-free medium, and the
samples were silenced in serum-free culture medium with
PiC-specific (Invitrogen and OriGene; two different siRNA
duplexes) or, as a negative control, scrambled siRNAs (100 nM)
using RNAiMAX (Life Technologies). After 4-h incubation, the
medium was completed with antibiotic-free 30% FBS-contain-
ingmedium. The next day, themediumwas changed to normal
growthmedium, and the cells were grown for 72 h. The efficacy
of the silencing was validated with Western blotting. For eval-
uation of mitochondrial morphology and fusion dynamics, the
cells were transfected with mtDsRed (1 g) and mtPA-GFP (1
g) plasmid DNAs using Lipofectamine 2000 (Life Technolo-
gies) 24 h before the experiment.
Growth Curves—Cell growth curves were performed in fibro-
blasts and HeLa cells. For all conditions, cells were counted in
duplicate wells for each time point. Cell counting was performed
using ahemocytometer. Eachgrowthcurvewasperformed in cells
from independent passages. For HeLa cells, growth curves were
started72hafter treatmentwithsiRNA;continuedknockdownfor
another 48 h was confirmed byWestern blotting.
Mitochondrial Bioenergetics—JO2 was measured in adherent
cells using the Seahorse XF24. Fibroblasts or HeLa cells were
seeded at 40,000/well the day before the experiment. For exper-
iments in intact cells, cells were washed two times in bicarbon-
ate-free DMEM containing the amount of glucose in which the
cells had been cultured (i.e. 5 or 25 mM) without or with 4 mM
glutamine, pH7.4 at 37 °C, and then 650l of thatmedium/well
was added as the final assay medium. Injections of oligomycin
(0.5 g/ml final concentration), FCCP (see figure legend for
final concentrations), and antimycin (1M final concentration)
were prepared in the respective assay media. To equilibrate
cells and degas the culture plate, cells were preincubated at
37 °C in environmental CO2 for 45 min.
For experiments in permeabilized cells, cells were washed
and preincubated as for intact cells. After the 45-min preincu-
bation, cells were washed again with mitochondrial assay solu-
tion (MAS) (32) (70 mM sucrose, 220 mM mannitol, 10 mM
KH2PO4, 5 mM MgCl2, 2 mM HEPES, 1 mM EGTA and 0.2%
(w/v) BSA, pH 7.2 at 37 °C), and then 450l/wellMAS contain-
ing 10 mM pyruvate, 2 mMmalate, 4 mM ADP (from a 1 M stock
that had been adjusted to pH 7.2), and permeabilizing reagent
(1 nM after optimization; Seahorse Biosciences) were added as
the final assaymedium. The final concentrations of ADP and sub-
strates are expected tobe saturatingbasedonexperiments in 5–10
g of isolatedmitochondria (32, 33). Oligomycin (2.5g/ml final)
and FCCP (4M final) were injected sequentially. Somewells only
received a final injection of oligomycin  FCCP to record phos-
phorylating JO2 for a longer time to monitor the stability of JO2;
after an increase in JO2 over the first5 min of the experiment,
JO2 remained stable for at least 10min prior to adding oligomycin
anduncoupler.Themix-wait-measureprotocolusedwas that rec-
ommended for isolatedmitochondria (32) that hasworkedwell in
our hands (33). To verify that cells were permeabilized, in some
experiments, a subset of wells contained succinate (5 mM) and
rotenone (1M) instead of pyruvate andmalate.
For both intact cell and permeabilized cell experiments, JO2
values were normalized to total cellular protein. Plates used for
both types of experiment were always plated at the same time,
allowing us to use the protein amount obtained from the intact
cell experiment for thepermeabilizedcell experiment (measure-
ment of protein from the latterwas confounded by the presence
of BSA in the MAS).
Mitochondrial Fusion Dynamics—Imaging measurements
were performed as described previously (16, 17). Briefly, cells
were incubated in a 0.25% BSA-containing extracellular
medium consisting of 121 mM NaCl, 5 mM NaHCO3, 4.7 mM
KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 2 mM CaCl2, 10 mM
glucose, and 10 mM Na-Hepes, pH 7.4, at 37 °C. Recordings of
mtPA-GFP and mtDsRed (512 	 512 pixels) were performed
using 488 and 561 nm laser lines at 0.25 s1 data acquisition
frequency using an LSM780 microscope and 63	/1.4 numerical
apertureApoplan oil objective. Experimentswere run at 37 °C. To
photoactivate PA-GFP (and photobleach Ds-Red) in 2P mode in
5 	 5-m areas, a pulsed laser system (760 nm; Chameleon,
Coherent, Inc.) was applied. Image analysis was done using either
Spectralyzer (custom designed) or Zen2010 (Carl Zeiss).
Mitochondrial dynamics was evaluated by two different
approaches. Spreading of PA-GFP from the area of photoacti-
vation was evaluated bymasking the 5	 5-mareas and quan-
tifying the time-dependent decay in the fluorescence ratio of
PA-GFP and DsRed. The ratio values in each region were nor-
malized to the peak reached during 2P excitation. Fusion events
were also countedmanually (34). Image analysis was performed
in Spectralyzer or Zen2010 imaging software.
Immunoblotting—For yeast studies, protein extraction from
yeast cells, SDS-PAGE, and immunoblotting were carried out
as described (35, 36). The antibodies used for the yeast studies
have been described previously (37–39). Images were captured
with the Fluorchem Q system (Cell Biosciences, Inc.), and rel-
ative protein levels were quantified using ImageJ. Statistical
analyses were performed with StatPlus. For mammalian cell
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studies, cells were lysed in radioimmune precipitation assay
buffer, and then lysates were clarified and assayed for protein
content using the bicinchoninic acid assay. Immunoblotting
was carried out as described previously (33, 14). The following
antibodies were used: SLC25A3 (1:500; Sigma SAB1400208;
rabbit), complex I 37-kDa subunit (1:1000; Abcam MS111;
mouse), complex II subunit A (succinate dehydrogenase sub-
unit A; 1:1000; AbcamMS204; mouse), complex III core 2 pro-
tein (1:1000; Abcam MS304; mouse), MFN1 (1:1000; rabbit
polyclonal provided by Richard Youle, National Institutes of
Health, Bethesda, MD), MFN2 (1:1000; mouse monoclonal
generated against MFN2(710–757)-GST and N-terminal pep-
tide CNSIVTVKKNKRIIM-OH provided by Heidi McBride,
McGill University, Montreal, Canada), OPA1 (1:1000; BD Bio-
sciences 612606; mouse), Drp1 (1:500; BD Biosciences 611738;
mouse), prohibitin (1:1000; Abcam 28172; rabbit), -tubulin
(1:1000; Cell Signaling Technology 2125; rabbit), cytochrome c
(1:1000; BD Pharmingen 556433), and GAPDH (1:10000;
Advanced Immunochemicals 8-GAPDH-r; rabbit). Prelimi-
nary experiments, not shown, using different amounts of
fibroblast and HeLa cell lysate were used to determine the
amount of protein that provided a signal that was within the
linear range of detection. In addition, proteins that were
used as loading controls were chosen because they did not
vary with PiC depletion.
Quantitative PCR—Total RNA was extracted from cells
using Trizol (Invitrogen). Purified RNAwas treated with RQ1
DNase (Promega,Madison,WI) for 30min at 37 °C. Total RNA
concentration was measured with a Qubit fluorometer (Invit-
rogen). RNAwas reverse transcribed using oligo(dT)20 primers
and SuperScript III (Invitrogen). Quantitative PCRs were done
using ITaq SYBR Green Supermix with ROXTM Reference Dye
(Bio-Rad) in 20-l reactions (20 ng of cDNA/reaction) using an
Eppendorf Mastercycler ep realplex. Primers were designed
using Eurofins Primer Design Tool: isoformA: forward primer,
5-CGCCGTGGAAGAGCAG-3; reverse primer, 5-CAATG-
CTGTATGTGTTGTGCC-3; isoform B: forward primer, 5-
CCGTGGAAGAGTACAGTTG-3; reverse primer, 5-AGC-
AGTGTGTGTAGACC-3. Custom oligos were purchased
from Eurofins MGWOperon (Huntsville, AL).
Statistics—The data are shown as the mean  S.E. of cells
recorded for at least three independent cultures unless it is
specified differently. Significance of differences was deter-
mined by unpaired Student’s t test or one- or two-way analysis
of variance with Tukey post hoc tests as appropriate (see figure
legends). p 0.05 was taken as significant.
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